Trends in prevalence, treatment use, and disease burden in patients with eosinophilic granulomatosis with polyangiitis in Japan: Real-world database analysis.

IF 1.8 4区医学 Q3 RHEUMATOLOGY

Modern Rheumatology Pub Date : 2024-08-20 DOI:10.1093/mr/road104

Ken-Ei Sada, Takeo Suzuki, Sandra Joksaite, Shinyoung Ju, John Logie, George Mu, Jeremiah Hwee, Hideaki Kunishige, Takeo Ishii, Amit Adlak, Harini Vadlamudi, Rafael Alfonso-Cristancho

{"title":"Trends in prevalence, treatment use, and disease burden in patients with eosinophilic granulomatosis with polyangiitis in Japan: Real-world database analysis.","authors":"Ken-Ei Sada, Takeo Suzuki, Sandra Joksaite, Shinyoung Ju, John Logie, George Mu, Jeremiah Hwee, Hideaki Kunishige, Takeo Ishii, Amit Adlak, Harini Vadlamudi, Rafael Alfonso-Cristancho","doi":"10.1093/mr/road104","DOIUrl":null,"url":null,"abstract":"Objectives: We report the prevalence of eosinophilic granulomatosis with polyangiitis (EGPA) and describe oral corticosteroid (OCS) use and disease burden before and after the mepolizumab approval in 2018 for EGPA in Japan.Methods: Two retrospective studies (GSK IDs: 218083 and 218084) used two databases: (1) the JMDC insurer database (Japanese health insurer claims) was used to report annual EGPA prevalence and OCS use in mepolizumab-treated patients and (2) Medical Data Vision database was used to report annual treatment use, OCS dose, relapses, and healthcare resource utilization in patients with EGPA.Results: EGPA prevalence (95% confidence interval) increased from 4.2 (0.1, 23.4) in 2005 to 58.6 (53.2, 64.5) per 1,000,000 in 2020. Median OCS dose (mg/day) decreased from a range of 4.8-7.7 during 2010-2017 to 4.5-4.8 during 2018-2020 (lowest dose in 2020). The proportion of patients with prednisolone-equivalent daily OCS dose >10 mg decreased from 2017 (11.9%) to 2020 (10.3%), while the median dose halved. The proportion of patients with EGPA relapses (64.3% to 41.6%) and hospitalization (27.8% to 23.6%) decreased from 2010 to 2020.Conclusions: EGPA prevalence increased between 2005 and 2020. With the introduction of mepolizumab for EGPA in 2018, real-world OCS use, relapses, and healthcare resource utilization decreased.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"988-998"},"PeriodicalIF":1.8000,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mr/road104","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: We report the prevalence of eosinophilic granulomatosis with polyangiitis (EGPA) and describe oral corticosteroid (OCS) use and disease burden before and after the mepolizumab approval in 2018 for EGPA in Japan.

Methods: Two retrospective studies (GSK IDs: 218083 and 218084) used two databases: (1) the JMDC insurer database (Japanese health insurer claims) was used to report annual EGPA prevalence and OCS use in mepolizumab-treated patients and (2) Medical Data Vision database was used to report annual treatment use, OCS dose, relapses, and healthcare resource utilization in patients with EGPA.

Results: EGPA prevalence (95% confidence interval) increased from 4.2 (0.1, 23.4) in 2005 to 58.6 (53.2, 64.5) per 1,000,000 in 2020. Median OCS dose (mg/day) decreased from a range of 4.8-7.7 during 2010-2017 to 4.5-4.8 during 2018-2020 (lowest dose in 2020). The proportion of patients with prednisolone-equivalent daily OCS dose >10 mg decreased from 2017 (11.9%) to 2020 (10.3%), while the median dose halved. The proportion of patients with EGPA relapses (64.3% to 41.6%) and hospitalization (27.8% to 23.6%) decreased from 2010 to 2020.

Conclusions: EGPA prevalence increased between 2005 and 2020. With the introduction of mepolizumab for EGPA in 2018, real-world OCS use, relapses, and healthcare resource utilization decreased.

查看原文本刊更多论文

日本嗜酸性肉芽肿伴多血管炎患者的患病率、治疗使用和疾病负担趋势：真实世界数据库分析。

目的：报告嗜酸性肉芽肿伴多血管炎（EGPA）的患病率，并描述2018年日本批准使用美波珠单抗治疗EGPA前后口服皮质类固醇（OCS）的使用和疾病负担。方法：两项回顾性研究（GSK ID:218083；218084）使用两个数据库：1）JMDC保险公司数据库（日本健康保险公司索赔）用于报告年度EGPA美波利珠单抗治疗患者的患病率和OCS使用情况；2）医学数据视觉数据库用于报告EGPA患者的年度治疗使用、OCS剂量、复发和医疗资源利用率（HCRU）。结果：EGPA患病率（95%置信区间）从2005年的4.2（0.123.4）增加到2020年的58.6（53.2,64.5）/100万。OCS的中位剂量（mg/天）从2010-2017年的4.8-7.7降至2018-2020年的4.5-4.8（2020年的最低剂量）。从2017年（11.9%）到2020年（10.3%），泼尼松等效日OCS剂量>10 mg的患者比例下降，而中位剂量减半。从2010年到2020年，EGPA复发（64.3%到41.6%）和住院（27.8%到23.6%）的患者比例下降。结论：EGPA患病率在2005年到2020年间增加。随着2018年美波利珠单抗用于EGPA，现实世界中OCS的使用、复发和HCRU减少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Modern Rheumatology RHEUMATOLOGY-

CiteScore

4.90

自引率

9.10%

发文量

146

审稿时长

1.5 months

期刊介绍： Modern Rheumatology publishes original papers in English on research pertinent to rheumatology and associated areas such as pathology, physiology, clinical immunology, microbiology, biochemistry, experimental animal models, pharmacology, and orthopedic surgery. Occasional reviews of topics which may be of wide interest to the readership will be accepted. In addition, concise papers of special scientific importance that represent definitive and original studies will be considered. Modern Rheumatology is currently indexed in Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, PubMed/Medline, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, EBSCO, CSA, Academic OneFile, Current Abstracts, Elsevier Biobase, Gale, Health Reference Center Academic, OCLC, SCImago, Summon by Serial Solutions